- Nexmos confirms effect in mouse model
Published in SCI-level academic journal ‘Plos One’
It is noteworthy whether the ‘DNA aptamer complex’ will open the possibility of treating Parkinson’s disease for which there is no suitable treatment.
Bioventure Nexmos (CEO Shim Jeong-wook) announced that the Parkinson’s disease-related effect was confirmed as a result of applying the self-developed antioxidant DNA aptamer complex (NXP031) to an animal model. This content was recently published in the SCI-level academic journal PLos One. The thesis is the research result of the research team led by Professor Yunseong Kim (pictured) of Rutgers University School of Medicine, co-founder of Nexmos. Professor Kim is one of the world’s leading authorities in the field of degenerative brain diseases.
Professor Kim said, “As a result of administering ‘NXP031’ for 8 weeks in a mouse model induced with Parkinson’s disease, it was confirmed that it improved motor neuropathy and suppressed dopaminergic neuronal degeneration and neuronal death. In an animal model to which MPTP, a Parkinson’s disease-inducing toxic substance, was administered, we confirmed the results of suppressing neuroinflammation in the brain with significant improvement in movement disorders and neuroprotective effects.” He also said, “The therapeutic efficacy of effectively blocking the progression of Parkinson’s disease was confirmed in an agglutination toxicity model by alpha-synuclein overexpression, not a simple chemical toxicity model.” In particular, he added that it is meaningful to prove the effect of treating Parkinson’s disease by increasing the concentration of active antioxidants in the blood and brain. Correspondent Jo Mun-sul